帕金森病的补充疗法干预:系统性审查和元分析
Fabio Sabbadin1, Michela Geraci2, Laura Nieddu3
1Department of Physical Medicine and Rehabilitation, Venice Hospital, Venice, Italy.
Frontiers in neurology
|December 12, 2025
概括
补充疗法对帕金森病 (PD) 患者显示适度益处,改善平衡和移动性. 由于研究的局限性和异质性,需要更严格的研究.
科学领域:
- 神经科学是一个神经科学.
- 康复医学 康复医学 康复医学
- 补充疗法 补充疗法 补充疗法
背景情况:
- 帕金森病 (PD) 是一种进展性神经退行性疾病,影响运动,非运动功能和生活质量 (QoL).
- 物理治疗是标准的,但音乐,舞蹈和艺术治疗等补充疗法正在为整体PD管理产生兴趣.
研究的目的:
- 系统地审查和元分析补充疗法与PD常规护理的有效性.
- 为了评估平衡,功能移动性,步态结 (FOG) 和PD患者的QoL的改善.
主要方法:
- 在PROSPERO (CRD42025636700) 中注册的,遵循PRISMA指南的系统审查和元分析.
- 搜索了PubMed,Cochrane,科学网,RCT,准RCT和CCT的数据库.
- 主要结果:平衡;次要结果:功能移动性,FOG,QoL. 使用Cochrane RoB2.2.进行偏差风险评估.
主要成果:
- 包括29项研究进行定性综合;17项研究进行元分析.
- 分析揭示了补充疗法对平衡和功能移动性的显著益处.
- 对偏见风险的评估表明,各项研究的方法质量很差.
结论:
- 补充疗法提供了适度的证据来改善帕金森病中的平衡和功能移动性.
- 改善QOL和FOG的证据不那么有说服力.
- 高异质性和方法上的局限性需要更严格的未来研究.
相关概念视频
01:24Parkinson's Disease: Treatment
940
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
940
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
01:22Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752